argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
April 18, 2023 01:00 ET
|
argenx SE
Amsterdam, the Netherlands – [04/18/2023] argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023 02:00 ET
|
argenx SE
Genmab and argenx have entered into a multiyear collaboration bringing together capabilities to jointly discover, develop and commercialize antibody therapies Discovery programs against two...
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
March 17, 2023 16:01 ET
|
argenx SE
March 17, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
March 15, 2023 09:25 ET
|
argenx SE
VYVGART is the first neonatal Fc receptor (FcRn) blocker approved in the UK for the treatment of adults living with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR)...
argenx Announces Planned Transition of Chief Operating Officer
March 02, 2023 01:00 ET
|
argenx SE
Karen Massey appointed as Chief Operating Officer, effective March 13, 2023Keith Woods to retire and serve as Advisor on argenx Board of Directors March 2, 2023 Amsterdam, the Netherlands — argenx...
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
March 02, 2023 01:00 ET
|
argenx SE
$173 million in fourth quarter and $401 million in full year 2022 VYVGART® (efgartigimod alfa-fcab) global net product sales FDA review ongoing for SC efgartigimod BLA with PDUFA target action date...
argenx Appoints Steve Krognes to Board of Directors
February 27, 2023 16:01 ET
|
argenx SE
February 27, 2023 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune...
argenx to Present at Upcoming Investor Conferences
February 27, 2023 01:00 ET
|
argenx SE
February 27, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
February 23, 2023 01:00 ET
|
argenx SE
February 23, 2023Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023 01:00 ET
|
argenx SE
January 27, 2023 Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases,...